525 related articles for article (PubMed ID: 29864213)
1. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
Goel A; Chen Q; Chhatwal J; Aggarwal R
J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
[TBL] [Abstract][Full Text] [Related]
2. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
Chugh Y; Dhiman RK; Premkumar M; Prinja S; Singh Grover G; Bahuguna P
PLoS One; 2019; 14(8):e0221769. PubMed ID: 31465503
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy.
Ruggeri M; Romano F; Basile M; Coretti S; Rolli FR; Drago C; Cicchetti A
Appl Health Econ Health Policy; 2018 Oct; 16(5):711-722. PubMed ID: 30039348
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study.
Tasavon Gholamhoseini M; Sharafi H; Hl Borba H; Alavian SM; Sabermahani A; Hajarizadeh B
BMJ Open; 2022 Jun; 12(6):e058757. PubMed ID: 35676019
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
Bourlière M; Gordon SC; Flamm SL; Cooper CL; Ramji A; Tong M; Ravendhran N; Vierling JM; Tran TT; Pianko S; Bansal MB; de Lédinghen V; Hyland RH; Stamm LM; Dvory-Sobol H; Svarovskaia E; Zhang J; Huang KC; Subramanian GM; Brainard DM; McHutchison JG; Verna EC; Buggisch P; Landis CS; Younes ZH; Curry MP; Strasser SI; Schiff ER; Reddy KR; Manns MP; Kowdley KV; Zeuzem S;
N Engl J Med; 2017 Jun; 376(22):2134-2146. PubMed ID: 28564569
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.
Zhou HJ; Cao J; Shi H; Naidoo N; Semba S; Wang P; Fan YF; Zhu SC
Front Public Health; 2021; 9():779215. PubMed ID: 34957030
[No Abstract] [Full Text] [Related]
8. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
Chahine EB; Kelley D; Childs-Kean LM
Ann Pharmacother; 2018 Apr; 52(4):352-363. PubMed ID: 29115151
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.
Aggarwal R; Chen Q; Goel A; Seguy N; Pendse R; Ayer T; Chhatwal J
PLoS One; 2017; 12(5):e0176503. PubMed ID: 28520728
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective.
Wei X; Zhao J; Yang L
BMJ Glob Health; 2020 Nov; 5(11):. PubMed ID: 33246983
[TBL] [Abstract][Full Text] [Related]
11. Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
Bloom DE; Khoury A; Srinivasan V
PLoS One; 2021; 16(7):e0252764. PubMed ID: 34292958
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China.
Yun H; Zhao G; Sun X; Shi L
BMJ Open; 2020 Aug; 10(8):e035224. PubMed ID: 32819983
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir/velpatasvir (Epclusa) for hepatitis C.
Med Lett Drugs Ther; 2016 Aug; 58(1501):107-8. PubMed ID: 27508349
[No Abstract] [Full Text] [Related]
14. Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection.
Summers BB
Drugs Today (Barc); 2018 Apr; 54(4):255-268. PubMed ID: 29869647
[TBL] [Abstract][Full Text] [Related]
15. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
Chahine EB; Sucher AJ; Hemstreet BA
Ann Pharmacother; 2017 Jan; 51(1):44-53. PubMed ID: 27609942
[TBL] [Abstract][Full Text] [Related]
16. Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir.
Schreiber J; McNally J; Chodavarapu K; Svarovskaia E; Moreno C
Hepatology; 2016 Sep; 64(3):983-5. PubMed ID: 27177605
[TBL] [Abstract][Full Text] [Related]
17. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
Younossi ZM; Stepanova M; Sulkowski M; Foster GR; Reau N; Mangia A; Patel K; Bräu N; Roberts SK; Afdhal N; Nader F; Henry L; Hunt S
Clin Infect Dis; 2016 Oct; 63(8):1042-1048. PubMed ID: 27444413
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C.
Sokol R
Am Fam Physician; 2017 May; 95(10):664-666. PubMed ID: 28671408
[No Abstract] [Full Text] [Related]
19. Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India.
Sood A; Duseja A; Kabrawala M; Amrose P; Goswami B; Chowdhury A; Sarin SK; Koshy A; Hyland RH; Lu S; Camus G; Stamm LM; Brainard DM; Subramanian GM; Prasad M; Bhatia S; Shah SR; Kapoor D; Shalimar ; Saraswat V
Hepatol Int; 2019 Mar; 13(2):173-179. PubMed ID: 30790229
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir and velpatasvir for the treatment of hepatitis C.
Jackson WE; Everson GT
Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):501-505. PubMed ID: 28468532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
